Comparing two drug combinations for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two oral drugs (vorolanib plus everolimus) versus the standard drug sunitinib in people with advanced clear cell kidney cancer that got worse after immunotherapy alone or with a targeted therapy. The goal is to see if the new combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced clear cell kidney cancer that got worse after prior treatment with an immunotherapy drug (like pembrolizumab or nivolumab) or with immunotherapy plus a targeted therapy.
- You are between 18 and 80 years old.
- You have at least one tumor that can be measured on scans and hasn't been treated with radiation.
- Your overall health is good enough for daily activities (Karnofsky score of 70 or higher).
- You have not had more than one prior systemic treatment for advanced kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.